Cipla Ltd
NSE:CIPLA

Watchlist Manager
Cipla Ltd Logo
Cipla Ltd
NSE:CIPLA
Watchlist
Price: 1 499.6 INR -0.56% Market Closed
Market Cap: 1.2T INR

Net Margin
Cipla Ltd

19.2%
Current
16%
Average
4.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
19.2%
=
Net Income
54.4B
/
Revenue
283.5B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
IN
Cipla Ltd
NSE:CIPLA
1.2T INR
19%
US
Eli Lilly and Co
NYSE:LLY
993.4B USD
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
508.5B USD
27%
CH
Roche Holding AG
SIX:ROG
256.1B CHF
15%
UK
AstraZeneca PLC
LSE:AZN
209.1B GBP
16%
CH
Novartis AG
SIX:NOVN
206.4B CHF
26%
US
Merck & Co Inc
NYSE:MRK
243.7B USD
30%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
33%
IE
Endo International PLC
LSE:0Y5F
209B USD
-126%
US
Pfizer Inc
NYSE:PFE
142.5B USD
16%
No Stocks Found

Cipla Ltd
Glance View

In the bustling heart of India's pharmaceutical landscape, Cipla Ltd. stands as a venerable name, tracing its roots back to 1935. Founded by Khwaja Abdul Hamied, Cipla embarked on a journey fueled by the vision of making healthcare accessible and affordable to the masses. Over decades, the company has morphed into a global pharmaceutical powerhouse, seamlessly integrating science and compassion. Cipla primarily operates through the production and sale of active pharmaceutical ingredients (APIs) and a wide array of generic medicines, catering to various therapeutic segments such as respiratory, anti-retroviral, urology, cardiology, and oncology. The company’s manufacturing prowess is underpinned by its state-of-the-art facilities, strategically located to serve markets across the globe, ensuring its competitive edge in quality and cost-efficiency. Cipla's revenue streams elegantly dance around its core philosophy—offering affordable medication without compromising quality. The company capitalizes on its robust R&D capabilities to develop and market generics that serve as cost-effective alternatives to patented medicines. Its business model thrives on the volume-driven sale of these generics, both in domestic and international markets. Additionally, Cipla reinforces its revenue through strategic partnerships and collaborations across the pharmaceutical value chain, and by out-licensing its products in various regions. By continually expanding its pipeline to include biosimilars and new drug delivery systems, Cipla not only strengthens its foothold in existing markets but also pioneers growth into new pharmaceutical frontiers.

CIPLA Intrinsic Value
HIDDEN
Show
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
19.2%
=
Net Income
54.4B
/
Revenue
283.5B
What is the Net Margin of Cipla Ltd?

Based on Cipla Ltd's most recent financial statements, the company has Net Margin of 19.2%.

Back to Top